Marie E Wood1, Pamela Kadlubek, Trang H Pham, Dana S Wollins, Karen H Lu, Jeffrey N Weitzel, Michael N Neuss, Kevin S Hughes. 1. Marie E. Wood, University of Vermont, Burlington, VT; Pamela Kadlubek, Trang H. Pham, and Dana S. Wollins, American Society of Clinical Oncology, Alexandria, VA; Karen H. Lu, MD Anderson Cancer Center, Houston, TX; Jeffrey N. Weitzel, City of Hope, Duarte, CA; Michael N. Neuss, Vanderbilt- Ingram Cancer Center, Nashville, TN; and Kevin S. Hughes, Avon Comprehensive Breast Evaluation Center, Mass General Hospital, Boston, MA.
Abstract
PURPOSE: Family history of cancer (CFH) is important for identifying individuals to receive genetic counseling/testing (GC/GT). Prior studies have demonstrated low rates of family history documentation and referral for GC/GT. METHODS: CFH quality and GC/GT practices for patients with breast (BC) or colon cancer (CRC) were assessed in 271 practices participating in the American Society of Clinical Oncology Quality Oncology Practice Initiative in fall 2011. RESULTS: A total of 212 practices completed measures regarding CFH and GC/GT practices for 10,466 patients; 77.4% of all medical records reviewed documented presence or absence of CFH in first-degree relatives, and 61.5% of medical records documented presence or absence of CFH in second-degree relatives, with significantly higher documentation for patients with BC compared with CRC. Age at diagnosis was documented for all relatives with cancer in 30.7% of medical records (BC, 45.2%; CRC, 35.4%; P ≤ .001). Referall for GC/GT occurred in 22.1% of all patients with BC or CRC. Of patients with increased risk for hereditary cancer, 52.2% of patients with BC and 26.4% of those with CRC were referred for GC/GT. When genetic testing was performed, consent was documented 77.7% of the time, and discussion of results was documented 78.8% of the time. CONCLUSION: We identified low rates of complete CFH documentation and low rates of referral for those with BC or CRC meeting guidelines for referral among US oncologists. Documentation and referral were greater for patients with BC compared with CRC. Education and support regarding the importance of accurate CFH and the benefits of proactive high-risk patient management are clearly needed.
PURPOSE: Family history of cancer (CFH) is important for identifying individuals to receive genetic counseling/testing (GC/GT). Prior studies have demonstrated low rates of family history documentation and referral for GC/GT. METHODS:CFH quality and GC/GT practices for patients with breast (BC) or colon cancer (CRC) were assessed in 271 practices participating in the American Society of Clinical Oncology Quality Oncology Practice Initiative in fall 2011. RESULTS: A total of 212 practices completed measures regarding CFH and GC/GT practices for 10,466 patients; 77.4% of all medical records reviewed documented presence or absence of CFH in first-degree relatives, and 61.5% of medical records documented presence or absence of CFH in second-degree relatives, with significantly higher documentation for patients with BC compared with CRC. Age at diagnosis was documented for all relatives with cancer in 30.7% of medical records (BC, 45.2%; CRC, 35.4%; P ≤ .001). Referall for GC/GT occurred in 22.1% of all patients with BC or CRC. Of patients with increased risk for hereditary cancer, 52.2% of patients with BC and 26.4% of those with CRC were referred for GC/GT. When genetic testing was performed, consent was documented 77.7% of the time, and discussion of results was documented 78.8% of the time. CONCLUSION: We identified low rates of complete CFH documentation and low rates of referral for those with BC or CRC meeting guidelines for referral among US oncologists. Documentation and referral were greater for patients with BC compared with CRC. Education and support regarding the importance of accurate CFH and the benefits of proactive high-risk patient management are clearly needed.
Authors: Eugene C Rich; Wylie Burke; Caryl J Heaton; Susanne Haga; Linda Pinsky; M Priscilla Short; Louise Acheson Journal: J Gen Intern Med Date: 2004-03 Impact factor: 5.128
Authors: Michael N Neuss; Christopher E Desch; Kristen K McNiff; Peter D Eisenberg; Dean H Gesme; Joseph O Jacobson; Mohammad Jahanzeb; Jennifer J Padberg; John M Rainey; Jeff J Guo; Joseph V Simone Journal: J Clin Oncol Date: 2005-08-08 Impact factor: 44.544
Authors: Katrina F Trivers; Laura-Mae Baldwin; Jacqueline W Miller; Barbara Matthews; C Holly A Andrilla; Denise M Lishner; Barbara A Goff Journal: Cancer Date: 2011-07-25 Impact factor: 6.860
Authors: J C Carroll; M Cappelli; F Miller; B J Wilson; E Grunfeld; C Peeters; A G W Hunter; C Gilpin; P Prakash Journal: Community Genet Date: 2008-01-15
Authors: Lucia I H Overbeek; Nicoline Hoogerbrugge; Joannes H J M van Krieken; Fokko M Nagengast; Theo J M Ruers; Marjolijn J L Ligtenberg; Rosella P M G Hermens Journal: Dis Colon Rectum Date: 2008-08 Impact factor: 4.585
Authors: Anita Y Kinney; Rachel Howell; Rachel Ruckman; Jean A McDougall; Tawny W Boyce; Belinda Vicuña; Ji-Hyun Lee; Dolores D Guest; Randi Rycroft; Patricia A Valverde; Kristina M Gallegos; Angela Meisner; Charles L Wiggins; Antoinette Stroup; Lisa E Paddock; Scott T Walters Journal: Contemp Clin Trials Date: 2018-09-18 Impact factor: 2.226
Authors: V Stefansdottir; H Skirton; O Th Johannsson; H Olafsdottir; G H Olafsdottir; L Tryggvadottir; J J Jonsson Journal: Fam Cancer Date: 2019-04 Impact factor: 2.375
Authors: Monica L Kasting; Claire C Conley; Aasha I Hoogland; Courtney L Scherr; Jongphil Kim; Ram Thapa; Maija Reblin; Cathy D Meade; M Catherine Lee; Tuya Pal; Gwendolyn P Quinn; Susan T Vadaparampil Journal: Psychooncology Date: 2019-04-11 Impact factor: 3.894
Authors: Tuya Pal; Devon Bonner; Deborah Cragun; Alvaro N A Monteiro; Catherine Phelan; Lily Servais; Jongphil Kim; Steven A Narod; Mohammad R Akbari; Susan T Vadaparampil Journal: Cancer Date: 2015-08-19 Impact factor: 6.860